Deep learning approaches for de novo drug design: An overview.

Journal: Current opinion in structural biology
Published Date:

Abstract

De novo drug design is the process of generating novel lead compounds with desirable pharmacological and physiochemical properties. The application of deep learning (DL) in de novo drug design has become a hot topic, and many DL-based approaches have been developed for molecular generation tasks. Generally, these approaches were developed as perĀ four frameworks: recurrent neural networks; encoder-decoder; reinforcement learning; and generative adversarial networks. In this review, we first introduced the molecular representation and assessment metrics used in DL-based de novo drug design. Then, we summarized the features of each architecture. Finally, the potential challenges and future directions of DL-based molecular generation were prospected.

Authors

  • Mingyang Wang
    Department of Ultrasound, Tianjin First Central Hospital, NanKai University, Tianjin, 300192, China.
  • Zhe Wang
    Department of Pathology, The Eighth Affiliated Hospital, Sun Yat-sen University, Shenzhen 518033, China.
  • Huiyong Sun
    College of Pharmaceutical Sciences, Zhejiang University , Hangzhou, Zhejiang 310058, China.
  • Jike Wang
    School of Computer Science, Wuhan University, Wuhan, Hubei 430072, China.
  • Chao Shen
    Department of Epidemiology, School of Public Health, Soochow University, Suzhou 215123, China.
  • Gaoqi Weng
    Hangzhou Institute of Innovative Medicine, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, Zhejiang, P. R. China.
  • Xin Chai
    College of Pharmaceutical Sciences at Zhejiang University, China.
  • Honglin Li
    Innovation Center for AI and Drug Discovery, East China Normal University, China.
  • Dongsheng Cao
    School of Pharmaceutical Sciences, Central South University, Changsha, China. oriental-cds@163.com.
  • Tingjun Hou
    College of Pharmaceutical Sciences, Zhejiang University , Hangzhou, Zhejiang 310058, China.